Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Mutational profiling in hematological malignancies

Cecilia Yeung, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, talks on mutational profiling in hematological malignancies using RNA sequencing (RNA-seq) and chromosomal genomic array testing. A considerable number of platforms are used for mutational profiling, including powerful instruments able to generate both RNA and DNA sequencing and deliver a comprehensive molecular profile, allowing to deliver next-generation sequencing (NGS) results rapidly. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Transcript (edited for clarity)

So, most of this testing occurs in the Fred Hutch CLIA laboratories. The chromosomal genomic array testing actually occurs at the Seattle Cancer Care Alliance inside our genetics lab, where we do a number of molecular tests. And the Fred Hutch CLIA laboratories, that is where we do the mutational profiling with a various number of platforms. Where, as you know, for next-generation sequencing, there is the Illumina platform, then recently, we’ve actually acquired two instruments in Genexus...

So, most of this testing occurs in the Fred Hutch CLIA laboratories. The chromosomal genomic array testing actually occurs at the Seattle Cancer Care Alliance inside our genetics lab, where we do a number of molecular tests. And the Fred Hutch CLIA laboratories, that is where we do the mutational profiling with a various number of platforms. Where, as you know, for next-generation sequencing, there is the Illumina platform, then recently, we’ve actually acquired two instruments in Genexus. And so these are pretty powerful instruments in that they’re able to do both RNA sequencing, as well as DNA sequencing. And they actually help us, in very rapid time, be able to sequence the genomes of cancers.

Read more...